The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1

This is a generated summary. It shows the 5 most-liked posts from a topic of 32, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
ID
i.dumitruTL215 Jul 2025#1

On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion.

Trying to work out what would count as evidence on Amylin analogue mechanism, before collecting any. This is the part I usually skip and it is the part that makes the rest useful.

If two explanations predict the same observation, observing it does not help. So: what observation would separate them?

48 likes 12mo
K
KStephanopoulosTL3Regular19 Jul 2025#13
i.dumitru, post #1: On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue mechanism, before collecting any. This is the part I usually skip and it is the part that makes the rest useful. If two explanations… Go to post

Everything in post #11 holds. The case it does not cover is the one I have.

An honest declaration on Amylin analogue mechanism: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.

24 likes in reply to #1 12mo
NS
n.serranoTL220 Jul 2025#21

The honest summary of the evidence base: a coherent mechanism, good phase 2 data in combination, and much less standalone human data than the volume of discussion implies.

One more caveat and then I will stop qualifying: the sample selected itself.

30 likes 12mo
SP
s.poulsenTL3Regular22 Jul 2025#30

For anyone arriving from searches on "amylin agonist": this subcategory discusses published clinical evidence and what it does and does not establish. It does not endorse or recommend the compounds discussed.

31 likes 12mo
MR
m.restrepoTL222 Jul 2025#31
j.nascimento, post #7: Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier. Go to post

Amylin analogue mechanism: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.

21 likes in reply to #7 12mo

Read the full topic (32 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. The question about Reading a combination trial that I…
ELPBLCMNBP+39 43 7.3k 12mo
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it
On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. A comparison question rather than a question about one…
NSOBGRARBD+2 6 2.4k 7mo
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
NEKCMALC+48 53 31k 13mo
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Cagrilintide alone:…
SBKRSICPMN+27 31 1.2k 22h
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
VMAHTTSVP 4 19k 11mo

Related topics — sharing the tags cagrisema, effect size, randomised trial

TopicParticipantsRepliesViewsActivity
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of c-cell question…
TKJEPPSDPN+61 65 1.3k 22mo
Measurement error in a self-reported exposure
Posting this under the heading it deserves: Measurement error in a self-reported exposure Everything below is what sits behind that. The question about measurement error that I actually want answered is the…
LHCKSVCW+117 129 45k 5mo
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. What changes if the standard account of claim built is wrong? I ask…
AWZCQZ 2 2k 18mo
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers…
IBDNOFID+15 19 4.4k 13mo
Retatrutide's phase 2 heart-rate signal and how to think about it
On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a…
MVBERMBJER+19 23 20k 7mo